Pharmafile Logo

Do Healthcare Providers Really Want to Go Back to In-person Meetings?

Healthcare professionals (HCPs) are increasingly seeking flexibility and convenience in their interactions with pharmaceutical and life sciences companies. This shift towards digital and blended approaches presents a valuable opportunity for life sciences organizations to enhance their communication and build stronger relationships with HCPs.

- PMLiVE

It is easy to assume that healthcare providers (HCPs) all want to go back to in-person meetings after having been confined to Zoom and Microsoft Teams meetings during the pandemic years. Anecdotally, however, we heard different things: many HCPs highlighted the convenience of the virtual format and considered this a silver lining from the long months of social and physical distancing. In a recent study by our group, the authors sought to understand this. They asked the very important question: what do HCPs really prefer when it comes to Pharma-sponsored small-group meetings such as advisory boards?

Preferred Meeting Format of HCPs

Male healthcare provider (HCP) attending a virtual meetingWhen asked about their preference for future advisory board meetings, a whopping 76% of surveyed HCPs opted for meetings with a virtual component (hybrid, real-time web, and/or asynchronous meetings). Less than a quarter of respondents preferred in-person–only meetings. Interestingly, the most popular meeting approach was found to be a mix of synchronous (real-time) and asynchronous (over-time, anytime) meetings. This finding highlights the importance of using varied formats to cater to all preferences and to avoid digital fatigue.

Another interesting finding was that the preference for hybrid meetings almost doubled between 2022 and 2023, while the preference for in-person–only meetings remained stable. In other words, while many HCPs undoubtedly do still enjoy in-person engagements, giving them the choice of how to attend will help ensure that everyone is happy…

Read the full article here.

 

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Digital technologies: Pharma’s answer to achieving net zero emissions?

As I wrote about earlier this year, it is clear that the climate crisis is no longer something for future generations to worry about, it’s already here and requires our urgent...

The Real-Time Health System: Accelerating Workflows with Data

Bree Bush, Vice President, Chief Data Officer at GE Healthcare, dives into simulation modeling and advanced analytical tools to optimize inpatient, procedural, and clinic capacity; the concept of “real-time healthcare”;...

The Future of eHealth: Contactless Health Monitoring

Laurence Pearce, CEO & Founder of Xim Ltd, creators of Lifelight®, discusses the need for personal health monitoring; traditional issues associated with population health screening; AI, machine learning, and computer...

Making Digital Trust and Privacy Accessible to Everyone

Mike Cook, CEO of IDENTOS, shares how his company is making digital trust and privacy accessible for patients, healthcare providers, payers, organizations, and connected devices. He also discusses “smart cities”...

Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

Congress eHuddle & Debrief Session: A Customer Story

How a Pharma team hosted daily MSL “eHuddles” during ASCO 2021 plus a post-congress debrief session using our asynchronous platform.

Healthcare Access and Payment Reform in the US

Chris Saxman, Senior Healthcare Executive, Head of Product Strategy at UCM Digital Health, shares his thoughts on the US healthcare system, including its flaws and how to fix it; the...

Advancing Drug Discovery with Structured and Intelligent Data

Michael Wilson and Craig Knox, co-founders of DrugBank, discuss how their comprehensive drug database can be used together with AI and machine learning for drug discovery and repurposing, clinical research,...

Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost

Lydia Zeller, CEO at Kiio, explores digital therapeutics, healthcare innovation, and Kiio’s innovative and personalized solutions for musculoskeletal (MSK) pain. She also shares her key leadership lessons and predictions for...

Accelerating Drug Development Timelines with Big Data Analytics

Barış Erdoğan, CEO of Clinerion, shares how medical data informatics and real-world EHR data can be used to improve the efficiency and effectiveness of patient searches, identification, and recruitment; clinical...